Join
Live feed
·
INSIDERFilingvia Quantisnow
BridgeBio Oncology Therapeutics Inc. logo

COO & Principal Financial Ofcr Elmelech Idan covered exercise/tax liability with 343 shares, decreasing direct ownership by 2% to 14,495 units (SEC Form 4) (for withholding tax)

ByQuantisnow·Wall Street's wire, on your screen.
BBOT· BridgeBio Oncology Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BBOT (BridgeBio Oncology Therapeutics Inc.) and more on Quantisnow.